Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients

Journal of Molecular Medicine

Volumn 92, Issue 5, 2014, Pages 487-495

  Hou, Xuwei ^a   Hu, Zhaohui ^b   Huang, Xiaohua ^c   Chen, Yan ^d   He, Xiuying ^a   Xu, Haiying ^a   Wang, Ningfu ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b TONGJI UNIVERSITY   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d LOMA LINDA UNIVERSITY   (United States)

Author keywords

Essential hypertension; Left ventricular hypertrophy; Osteopontin; Polymorphisms

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OSTEOPONTIN; THROMBIN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CELL SIZE; CELL SURFACE; DISEASE SEVERITY; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENETIC RISK; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BLOOD; CELL CULTURE; COMPLICATION; GENETICS; GENOTYPE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; RAT; WISTAR RAT;

ANIMALS; CELLS, CULTURED; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; OSTEOPONTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RATS, WISTAR;

EID: 84899935341     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1099-9     Document Type: Article

References (42)

1. Zhan S, Liu M, Yao W, Hu Y, Li L, Zhu G, Sun N, Dai L (2002) Prevalence and relevant factors on echocardiographic left ventricular hypertrophy among community-based hypertensive patients in Shanghai. Zhonghua Liu Xing Bing Xue Za Zhi 23(3):182-185
2. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Giannattasio C, Grassi G, Sega R (2008) Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 26(8):1602-1611
3. Petrovic D, Stojimirovic B (2008) Left ventricular hypertrophy in patients treated with regular hemodialyses. Med Pregl 61(7-8):369-374
4. Kaplinsky E (1994) Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther 8(Suppl 3):549-556
5. Tovillas-Moran FJ, Vilaplana-Cosculluela M, Zabaleta-del-Olmo E, Dalfo-Baque A, Galceran JM, Coca A (2010) Cardiovascular morbidity and mortality and electrocardiographic criteria of left ventricular hypertrophy in hypertensive patients treated in primary care. Med Clin (Barc) 135(9):397-401
6. Ozawa M, Tamura K, Okano Y, Matsushita K, Ikeya Y, Masuda S, Wakui H, Dejima T, Shigenaga A, Azuma K et al (2009) Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin Exp Hypertens 31(8):669-679
7. Schirmer H, Lunde P, Rasmussen K (1999) Prevalence of left ventricular hypertrophy in a general population: the Tromso Study. Eur Heart J 20(6):429-438 (Pubitemid 29116539)
8. Bella JN, Goring HH (2012) Genetic epidemiology of left ventricular hypertrophy. Am J Cardiovasc Dis 2(4):267-278
9. Arnett DK (2000) Genetic contributions to left ventricular hypertrophy. Curr Hypertens Rep 2(1):50-55
10. Xu HY, Hou XW, Wang LF, Wang NF, Xu J (2010) Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem 335(1-2):13-17
11. Kurbanova D, Eliseyeva M (2010) Genetic background of left ventricular hypertrophy in Uzbek hypertensive men. Turk Kardiyol Dern Ars 38(7):466-472
12. El-Shehaby AM, El-Khatib MM, Marzouk S, Battah AA (2012) Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients. Scand J Clin Lab Invest 73(1):75-81
13. Kaufman BD, Desai M, Reddy S, Osorio JC, Chen JM, Mosca RS, Ferrante AW, Mital S (2008) Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. J Card Fail 14(9):760-767
14. Giachelli CM, Steitz S (2000) Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 19(7):615-622
15. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB (2009) Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 76(1):32-43
16. Dahiya S, Givvimani S, Bhatnagar S, Qipshidze N, Tyagi SC, Kumar A (2011) Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J Immunol 187(5):2723-2731
17. Rosenberg M, Meyer FJ, Gruenig E, Lutz M, Lossnitzer D, Wipplinger R, Katus HA, Frey N (2012) Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension. Eur J Clin Investig 42(9):933-942
18. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA (1997) Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 96(9): 3063-3071 (Pubitemid 27500109)
19. Trivedi T, Franek BS, Green SL, Kariuki SN, Kumabe M, Mikolaitis RA, Jolly M, Utset TO, Niewold TB (2011) Osteopontin alleles are associated with clinical characteristics in systemic lupus erythematosus. J Biomed Biotechnol 2011:802581
20. Mochida S, Hashimoto M, Matsui A, Naito M, Inao M, Nagoshi S, Nagano M, Egashira T, Mishiro S, Fujiwara K (2004) Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 313(4):1079-1085
21. Miyazaki T, Ono M, Qu WM, Zhang MC, Mori S, Nakatsuru S, Nakamura Y, Sawasaki T, Endo Y, Nose M (2005) Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice. Eur J Immunol 35(5):1510-1520 (Pubitemid 40691432)
22. Kim Y, Lee C (2008) Haplotype analysis revealed a genetic influence of osteopontin on large artery atherosclerosis. J Biomed Sci 15(4): 529-533
23. Hasegawa M, Nakoshi Y, Iino T, Sudo A, Segawa T, Maeda M, Yoshida T, Uchida A (2009) Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol 36(2): 240-245
24. Jiang Y, Yao M, Liu Q, Zhou C (2013) OPN gene polymorphisms influence the risk of knee OA and OPN levels in synovial fluid in a Chinese population. Arthritis Res Ther 15(1):R3
25. Su FF, Shi MQ, Guo WG, Liu XT, Wang HT, Lu ZF, Zheng QS (2012) High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes. Mediat Inflamm 2012:805149
26. Lee JH, Pyon JK, Lee SH, Lee YJ, Kang SG, Kim CH, Kim DW, Nam HS, Park YH, Jeong DJ et al (2011) Greater expression of TC21/R-ras2 in highly aggressive malignant skin cancer. Int J Dermatol 50(8):956-960
27. Kusuyama T, Yoshiyama M, Omura T, Nishiya D, Enomoto S, Matsumoto R, Izumi Y, Akioka K, Takeuchi K, Iwao H et al (2005) Angiotensin blockade inhibits osteopontin expression in non-infarcted myocardium after myocardial infarction. J Pharmacol Sci 98(3):283-289 (Pubitemid 41296409)
28. Hou XW, Wang LF, Wang N, Pang D, Hui B, Zhou YL, He X (2008) The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives. Clin Chim Acta 388(1-2):200-203 (Pubitemid 50012594)
29. Shi B, Ni Z, Cai H, Zhang M, Mou S, Wang Q, Cao L, Yu Z, Yan Y, Qian J (2010) High-sensitivity C-reactive protein: an independent risk factor for left ventricular hypertrophy in patients with lupus nephritis. J Biomed Biotechnol 2010:373426
30. Monfared A, Salari A, Kazemnezhad E, Lebadi M, Khosravi M, Mehrjardi NK, Rahimifar S, Amini N (2013) Association of left ventricular hypertrophy with high-sensitive C-reactive protein in hemodialysis patients. Int Urol Nephrol. 2013 Jan 11. [Epub ahead of print]
31. Francia P, Balla C, Ricotta A, Uccellini A, Frattari A, Modestino A, Borro M, Simmaco M, Salvati A, De Biase L et al (2011) Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. Int J Cardiol 153(3):306-310
32. Schipper ME, Scheenstra MR, van Kuik J, van Wichen DF, van der Weide P, Dullens HF, Lahpor J, de Jonge N, De Weger RA (2011) Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support. J Heart Lung Transplant 30(7):805-810
33. Nakayama H, Nagai H, Matsumoto K, Oguro R, Sugimoto K, Kamide K, Ohishi M, Katsuya T, Okamoto H, Maeda M et al (2011) Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese population. Hypertens Res 34(10):1141-1146
34. de las Fuentes L, Gu CC, Mathews SJ, Reagan JL, Ruthmann NP, Waggoner AD, Lai CF, Towler DA, Davila-Roman VG (2008) Osteopontin promoter polymorphism is associated with increased carotid intima-media thickness. J Am Soc Echocardiogr 21(8):954-960
35. Brenner D, Labreuche J, Touboul PJ, Schmidt-Petersen K, Poirier O, Perret C, Schonfelder J, Combadiere C, Lathrop M, Cambien F et al (2006) Cytokine polymorphisms associated with carotid intimamedia thickness in stroke patients. Stroke 37(7):1691-1696 (Pubitemid 44297714)
36. Chu M, Yang P, Hou S, Li F, Chen Y, Kijlstra A (2011) Behcet's disease exhibits an increased osteopontin serum level in active stage but no association with osteopontin and its receptor gene polymorphisms. Hum Immunol 72(6):525-529
37. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, Ni L, Zhang D, Li N, Zhang J (2005) Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 32(3):410-416 (Pubitemid 40381409)
38. Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, Kao SY (2010) The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol 46(4):302-306
39. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D (1999) The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274(51):36328-36334
40. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L (2001) Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 276(30):28261-28267
41. Hou P, Troen T, Ovejero MC, Kirkegaard T, Andersen TL, Byrjalsen I, Ferreras M, Sato T, Shapiro SD, Foged NT et al (2004) Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone 34(1):37-47 (Pubitemid 38142432)
42. Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27(11):2302-2309 (Pubitemid 350203943)